Search

Hiroshi Nagabukuro

from Natick, MA
Age ~53

Hiroshi Nagabukuro Phones & Addresses

  • 6 Fox Hill Dr, Natick, MA 01760
  • Fanwood, NJ
  • Metuchen, NJ
  • Evanston, IL
  • Minneapolis, MN
  • Tallahassee, FL
  • Newton Center, MA
  • Union, NJ
  • Osage, MN
  • Kearny, NJ

Work

Company: Takeda pharmaceuticals 2012 Address: Fujisawa, Kanagawa, Japan Position: Associate director

Education

Degree: PhD School / High School: The University of Tokyo 2004 to 2006 Specialities: Pharmacology

Skills

Biotechnology • Biochemistry • Assay Development

Industries

Higher Education

Resumes

Resumes

Hiroshi Nagabukuro Photo 1

Adjunct Professor

View page
Location:
6 Fox Hill Dr, Natick, MA 01760
Industry:
Higher Education
Work:
Takeda Pharmaceuticals - Fujisawa, Kanagawa, Japan since 2012
Associate Director

Merck Research Laboratories - Boston, MA 2011 - 2012
Research Fellow

Merck Research Laboratories - Rahway, NJ / Boston, MA 2007 - Jan 2011
Sr Research Biologist

Florida State University - Tallahassee, Florida Area Mar 2006 - Mar 2007
Visiting Scientist, Psychology Departement

Takeda Pharmaceuticals 1996 - 2007
Assistant Research Head
Education:
The University of Tokyo 2004 - 2006
PhD, Pharmacology
Nagoya University 1989 - 1993
MS, Animal Science
Skills:
Biotechnology
Biochemistry
Assay Development

Publications

Us Patents

Iminopyridine Derivative And Use Thereof

View page
US Patent:
20100016315, Jan 21, 2010
Filed:
Oct 22, 2007
Appl. No.:
12/446960
Inventors:
Masato Yoshida - Osaka, JP
Tomohiko Suzaki - Osaka, JP
Yasuhisa Kohara - Osaka, JP
Haruhiko Kuno - Osaka, JP
Hiroshi Nagabukuro - Fanwood NJ, US
Reiko Saikawa - Osaka, JP
Yuuichi Okabe - Osaka, JP
Shigemitsu Imai - Osaka, JP
International Classification:
A61K 31/5377
C07D 213/78
A61K 31/44
C07D 413/10
A61P 13/02
C12Q 1/02
US Classification:
5142355, 546310, 514352, 544124, 435 29
Abstract:
Provided are an iminopyridine derivative having a selective αadrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like, and a screening method for a compound having an αadrenergic receptor antagonistic action. An αadrenergic receptor antagonist containing a compound represented by the formula:wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an αadrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with bladder outlet obstruction.

Combination Therapy Using A Beta 3 Adrenergic Receptor Agonists And An Antimuscarinic Agent

View page
US Patent:
20120202819, Aug 9, 2012
Filed:
Sep 27, 2010
Appl. No.:
13/500574
Inventors:
Scott D. Edmondson - Clark NJ, US
Hiroshi Nagabukuro - Natick MA, US
William S. Denney - Somerville MA, US
Tara F. Frenki - Blue Bell PA, US
Assignee:
Merck Sharp & Dohme Corporation - Rahway NJ
International Classification:
A61K 31/427
A61K 31/517
A61K 31/501
A61K 31/502
A61K 31/513
A61P 13/10
A61K 31/4196
A61K 31/437
A61K 31/519
A61K 31/4725
A61K 31/46
A61K 31/445
A61K 31/428
A61K 31/4439
US Classification:
514248, 514370, 514367, 5142662, 51425205, 514274, 514269, 514343, 514383, 514299, 5142595, 514305, 514278, 514327
Abstract:
Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective Mantagonist. Such combination therapy provides improved efficacy and/or reduced side effects.
Hiroshi Nagabukuro from Natick, MA, age ~53 Get Report